1 option
Clinical review report : Teduglutide (Revestive) (Shire Pharmaceuticals Ireland Limited) : indication: treatment of adults and pediatric patients one year of age and above with short bowel syndrome who are dependent on parenteral support / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Series:
- Common drug review clinical review report.
- Common drug review clinical review report
- Language:
- English
- Subjects (All):
- Outcome assessment (Medical care).
- Physical Description:
- 1 online resource (89 pages) : illustrations.
- Edition:
- Final edition.
- Place of Publication:
- Ottawa, ON : CADTH, 2020.
- Summary:
- The objective of the current CDR review was to perform a systematic review of the beneficial and harmful effects of teduglutide subcutaneous injection (Revestive) for the treatment of pediatric patients one year of age and above with Short bowel syndrome who are dependent on parenteral support.
- Notes:
- Description based on publisher supplied metadata and other sources.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.